Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous rituximab with CHOP in previously untreated diffuse large B-cell lymphoma
2012-000669-19Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, rituximab and hyaluronidase human in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Jun 2012; status: completed.
02
Drugs
rituximabrituximab and hyaluronidase human
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2012-000669-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000669-19.